STOCK TITAN
  1. Home
  2. News
  3. MEIP

MEI Pharma Inc - MEIP STOCK NEWS

Welcome to our dedicated news page for MEI Pharma (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEI Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEI Pharma's position in the market.

News
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Rhea-AI Summary
MEI Pharma Board decides not to proceed with second capital return, prioritizes clinical development of voruciclib and ME-344. Voruciclib and ME-344 show promising clinical data for cancer therapies. Company aims to optimize resources and extend operational runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
management
-
News
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Rhea-AI Summary
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the decision to advance ME-344 via a new formulation for increased biological activity and commercial opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
clinical trial
-
News
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Rhea-AI Summary
MEI Pharma, Inc. (MEIP) announced that David Urso will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum. Investors can listen to the live webcast on April 16 at 1:30 PM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
News
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Rhea-AI Summary
MEI Pharma, Inc. initiates enrollment in an expansion cohort for a Phase 1 study evaluating voruciclib and venetoclax in R/R AML patients. Positive anti-leukemic activity and Mcl-1 decreases observed with no dose-limiting toxicities. Promising early results show good treatment tolerance and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
clinical trial
-
News
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Rhea-AI Summary
MEI Pharma, Inc. reported positive results for the three and six months ended December 31, 2023. The company highlighted ongoing clinical studies for voruciclib and ME-344, with strong investigator support. MEI presented data from Phase 1 trials at major conferences. Financially, MEI had $59.5 million in cash with no debt, and operational expenses decreased due to program changes. The company expects to report more clinical data in the near future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
earnings
-
News
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced the design of the ongoing Phase 1b study of ME-344, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor, in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients. The study will be presented at the 2024 ASCO Gastrointestinal Cancers Symposium. The combination is intended to create metabolic synthetic lethality to address known resistance mechanisms to standard-of-care cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences clinical trial
News
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, alone and in combination with venetoclax in patients with acute myeloid leukemia or B-cell malignancies. Safety profile observed suggests no overlapping toxicity. Initial results from correlative studies demonstrate on-target reductions in Mcl-1 and RNA Pol II p-S2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
clinical trial
-
News
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
Rhea-AI Summary
MEI Pharma (MEIP) reports strong clinical study support for drug candidates voruciclib and ME-344, with data from Phase 1 trials expected in 2024. Recent highlights include dosing of the first patient in a Phase 1b study for ME-344, and an abstract presentation at the ASH Annual Meeting. Financially, the company recognized revenue of $65.3 million for the quarter ended September 30, 2023, and reported net income of $56.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
-
News
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
Rhea-AI Summary
MEI Pharma, Inc. (MEIP) to present at Stifel 2023 Healthcare Conference, offering business update. Investors invited to live webcast on November 15 at 8:35 AM Eastern Time. Replay available on www.meipharma.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
News
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a special cash dividend of $1.75 per share of common stock, payable on December 6, 2023. The dividend will be characterized for tax purposes as a return of capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
dividends
Stock MEIP logo
MEI Pharma Inc

Nasdaq:MEIP

MEIP Rankings

#5108 Ranked by Market Cap
#1883 Ranked by Stock Gains
N/A Ranked by Dividends

MEIP Stock Data

21.79M
4.94M
0.54%
47.58%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MEIP

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.